Journal
HEADACHE
Volume 60, Issue 3, Pages 649-653Publisher
WILEY
DOI: 10.1111/head.13749
Keywords
migraine; treatment of migraine attack; migraine prevention; hypertension; coronary artery disease; stroke
Categories
Funding
- Allergan
- Electrocore
- MSD
- Pfizer
- German Research Council (DFG)
- German Ministry of Education and Research (BMBF)
- European Union
Ask authors/readers for more resources
Premises Patients with migraine have a co-morbidity with vascular diseases such as hypertension, coronary heart disease, and stroke. Problem This overview gives recommendations for the therapy of acute migraine attacks and for migraine prevention in patients with vascular diseases. In particular, the use of triptans in patients with vascular diseases is discussed. Potential Solutions Currently, there is a contraindication for the use of the triptans in patients with vascular disease, although there is no evidence that triptans increase the risk of heart attacks or stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available